159992 创新药
已收盘 11-22 15:00:00
资讯
新帖
简况
创新药子公司二闯IPO 四环医药“减负”
贝果财经 · 11-22 23:06
创新药子公司二闯IPO 四环医药“减负”
微芯生物拟定增9.6亿加码创新药 前9月亏5108万研发投入降23.6%
长江商报 · 11-22 08:29
微芯生物拟定增9.6亿加码创新药 前9月亏5108万研发投入降23.6%
ETF日报：创新药板块仍将是医药板块热门的投资赛道之一，估值修复空间或值得期待
新浪基金 · 11-21 22:44
ETF日报：创新药板块仍将是医药板块热门的投资赛道之一，估值修复空间或值得期待
信立泰：仿制药龙头押注创新药
微博财经-财道工作室 · 11-21 19:37
信立泰：仿制药龙头押注创新药
【港股通】中国生物制药(01177)：创新药用于晚期肝细胞癌一线治疗新适应症上市申请获受理
金吾财讯 · 11-21 12:30
【港股通】中国生物制药(01177)：创新药用于晚期肝细胞癌一线治疗新适应症上市申请获受理
中国生物制药(01177.HK)创新药的新适应症上市申请获受理
阿斯达克财经 · 11-21 12:10
中国生物制药(01177.HK)创新药的新适应症上市申请获受理
创新药全线躁动！月底国谈结果预期值抬升？
智通财经网 · 11-20 21:15
创新药全线躁动！月底国谈结果预期值抬升？
众生药业(002317.SZ)子公司众生睿创创新药RAY1225注射液减重Ⅱ期临床试验结果达到预期目的
智通财经 · 11-20 20:23
众生药业(002317.SZ)子公司众生睿创创新药RAY1225注射液减重Ⅱ期临床试验结果达到预期目的
微芯生物：拟定增募资不超9.6亿元
美港电讯 · 11-20 19:16
微芯生物：拟定增募资不超9.6亿元
微芯生物(688321.SH)拟定增募资不超9.6亿元 用于创新药研发项目等
智通财经 · 11-20 19:07
微芯生物(688321.SH)拟定增募资不超9.6亿元 用于创新药研发项目等
盟科药业-U上涨5% 创新药发展受关注
智选洞察 · 11-20 13:02
盟科药业-U上涨5% 创新药发展受关注
创新药板块震荡走强 贝达药业涨超10%
市场资讯 · 11-20
创新药板块震荡走强 贝达药业涨超10%
中国医药：医疗设备招标有望复苏，创新药出海成果丰硕
招银国际 · 11-18
中国医药：医疗设备招标有望复苏，创新药出海成果丰硕
海思科最新公告：获得创新药HSK44459片IND申请《受理通知书》
证券之星 · 11-18
海思科最新公告：获得创新药HSK44459片IND申请《受理通知书》
海思科(002653.SZ)创新药HSK44459片临床试验申请获受理
智通财经 · 11-18
海思科(002653.SZ)创新药HSK44459片临床试验申请获受理
健康元：公司新型小分子糖皮质激素创新药目前正在准备IND阶段
每日经济新闻 · 11-18
健康元：公司新型小分子糖皮质激素创新药目前正在准备IND阶段
国盛证券：国内创新药产业趋势由license-in逐步转为license-out
智通财经 · 11-18
国盛证券：国内创新药产业趋势由license-in逐步转为license-out
创新药龙头百济神州：造血能力不足三季报续亏，“烧钱模式”不休
证券之星 · 11-18
创新药龙头百济神州：造血能力不足三季报续亏，“烧钱模式”不休
科伦药业(002422.SZ)：创新药物SKB535新药临床试验申请获批
智通财经 · 11-18
科伦药业(002422.SZ)：创新药物SKB535新药临床试验申请获批
众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药
美港电讯 · 11-17
众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.712,"timestamp":1732258989000,"preClose":0.744,"halted":0,"volume":601439165,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.032,"latestTime":"11-22 15:00:00","open":0.743,"high":0.743,"low":0.711,"amount":437000000,"amplitude":0.043,"askPrice":0.713,"askSize":19646,"bidPrice":0.712,"bidSize":1387,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":0.744,"symbolType":"fund","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":0.818,"lowLimit":0.67,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"committee":0.50493,"marketValue":0,"floatMarketCap":0,"changeRate":-0.043,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。","discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159992/wiki","defaultTab":"wiki","newsList":[{"id":"2485245806","title":"创新药子公司二闯IPO 四环医药“减负”","url":"https://stock-news.laohu8.com/highlight/detail?id=2485245806","media":"贝果财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485245806?lang=zh_cn&edition=full","pubTime":"2024-11-22 23:06","pubTimestamp":1732287960,"startTime":"0","endTime":"0","summary":"取而代之的是，四环医药方面认为分拆“亦可以增强轩竹生物的公司治理及四环医药的营运管理能力”。轩竹生物由四环医药于2018年9月设立，通过整合四环医药创新药研发管线成为独立运营的创新药企业。截至11月12日，四环医药已支付约2.1亿元。医美业务仍需投入两次分拆轩竹生物上市，四环医药意在“腾笼换鸟”。在推动轩竹生物科创板IPO时，四环医药在公告中表示，完成分拆能帮助公司及子公司进一步向医美业务聚焦和转型发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-11-22/doc-incwyyts3350167.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-22/doc-incwyyts3350167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1515","159992","BK1161","BK1574","06978","00460","BK1593","BK1600"],"gpt_icon":0},{"id":"2485779476","title":"微芯生物拟定增9.6亿加码创新药 前9月亏5108万研发投入降23.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485779476","media":"长江商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485779476?lang=zh_cn&edition=full","pubTime":"2024-11-22 08:29","pubTimestamp":1732235387,"startTime":"0","endTime":"0","summary":"2024年前三季度，微芯生物的研发投入金额为2.46亿元，同比减少23.55%，占当期营业收入的比例为51.05%，同比减少41.11个百分点。2019年至今，微芯生物的研发投入金额合计达13.88亿元。根据目前在研管线及未来研发计划，微芯生物此次计划使用定增募集资金7.1亿元用于原创新药的研发项目，以加快研发进展，增强公司研发和自主创新能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122084134abd5e9ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122084134abd5e9ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688321"],"gpt_icon":0},{"id":"2485649062","title":"ETF日报：创新药板块仍将是医药板块热门的投资赛道之一，估值修复空间或值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2485649062","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485649062?lang=zh_cn&edition=full","pubTime":"2024-11-21 22:44","pubTimestamp":1732200240,"startTime":"0","endTime":"0","summary":"今日大盘全天窄幅整理，截至收盘，上证指数涨0.07%报3370.4点，深证成指跌0.07%，创业板指跌0.09%。量能方面，A股全天成交1.66万亿元，环比持平。盘面上，计算机、证券、有色金属等涨幅相对较好，通信、石油有所回调。但随着“特朗普交易”的退潮，美元指数回落，金价本周止跌。黄金基金ETF今日上涨1.4%，黄金股票ETF上涨1.53%。随着政策转暖以及国产创新药企的创新成果逐步兑现，创新药板块仍将是医药板块热门的投资赛道之一，估值修复空间或值得期待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/etf/2024-11-21/doc-incwvyre1169607.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2024-11-21/doc-incwvyre1169607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK4585","159938","09939","BK1515","BK4550","FDN","BK1161","BK4588","159992","BK1574"],"gpt_icon":0},{"id":"2485467455","title":"信立泰：仿制药龙头押注创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485467455","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485467455?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:37","pubTimestamp":1732189020,"startTime":"0","endTime":"0","summary":"多款创新产品上市信立泰营收过去主要依赖仿制药，但公司多年来积极布局创新转型，研发投入不断加大，同时重视研发团队建设。其中，苯甲酸福格列汀片和阿利沙坦酯氨氯地平片，分别是1类新药、2类新药，表明信立泰创新转型产出重要成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/wbstock/2024-11-21/doc-incwvpzh4575306.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2024-11-21/doc-incwvpzh4575306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0196","BK1161","BK1574","BK0187","BK0239","159992","002294","BK0028","BK0183","06978"],"gpt_icon":0},{"id":"2485871114","title":"【港股通】中国生物制药(01177)：创新药用于晚期肝细胞癌一线治疗新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2485871114","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485871114?lang=zh_cn&edition=full","pubTime":"2024-11-21 12:30","pubTimestamp":1732163451,"startTime":"0","endTime":"0","summary":"基于这一积极成果，本集团近期已向中国国家药品监督管理局药品审评中心递交新适应症上市申请并获得受理。中国是肝癌高发地区，2020年中国新发病例41万，占全球新发病例的45%，死亡病例达39万，占全球死亡病例的47%。在中国，约70%的HCC患者初诊时即为中晚期2。但目前针对晚期HCC的治疗选择有限，随着免疫治疗的推广，免疫联合抗血管治疗逐步成为一线系统治疗的新选择。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948164","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1574","HSCEI","BK1589","BK1521","06978","HSTECH","159992","BK1191","YANG","BK1161","BK1515"],"gpt_icon":0},{"id":"2485482029","title":"中国生物制药(01177.HK)创新药的新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2485482029","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485482029?lang=zh_cn&edition=full","pubTime":"2024-11-21 12:10","pubTimestamp":1732162200,"startTime":"0","endTime":"0","summary":"基于这一积极成果，集团近期已向中国国家药品监督管理局药品审评中心递交新适应症上市申请并获得受理。公司指，一线治疗晚期肝细胞癌是盐酸安罗替尼胶囊申报上市的第10个适应症，有望为晚期肝细胞癌患者提供一种更安全、更便捷的治疗方案。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419121920492_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419121920492_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1398470&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1574","BK1589","BK1521","06978","159992","BK1191","BK1161","BK1515"],"gpt_icon":0},{"id":"2484119843","title":"创新药全线躁动！月底国谈结果预期值抬升？","url":"https://stock-news.laohu8.com/highlight/detail?id=2484119843","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484119843?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:15","pubTimestamp":1732108540,"startTime":"0","endTime":"0","summary":"近期，随着2024年国谈结果公布的临近，医药领域的利好政策相继出台，投资者对于医药板块，特别是创新药板块的关注度不断提高。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20241120/20241120211416_54088.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241120/20241120211416_54088.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2484903031","title":"众生药业(002317.SZ)子公司众生睿创创新药RAY1225注射液减重Ⅱ期临床试验结果达到预期目的","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903031","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484903031?lang=zh_cn&edition=full","pubTime":"2024-11-20 20:23","pubTimestamp":1732105389,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业 公告，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于超重/肥胖患者的Ⅱ期临床试验，于近日获得子研究的顶线分析数据。初步结果表明，RAY1225注射液在中国成人超重/肥胖参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。RAY1225注射液用于肥胖/超重患者与2型糖尿病患者的两项Ⅱ期临床研究仍在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","06978","BK0188","BK1574","159992","002317","BK1141","03347","BK1161","BK1576","BK0239","BK1583"],"gpt_icon":0},{"id":"2484999881","title":"微芯生物：拟定增募资不超9.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484999881","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484999881?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:16","pubTimestamp":1732101392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688321","06978","BK1161","BK1574","159992","BK0239"],"gpt_icon":0},{"id":"2484196420","title":"微芯生物(688321.SH)拟定增募资不超9.6亿元 用于创新药研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2484196420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484196420?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:07","pubTimestamp":1732100871,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司拟向特定对象发行股票，募集资金总额不超过9.6亿元(含本数)，募集资金总额扣除相关发行费用后的净额将用于投资：创新药研发项目、补充流动资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","688321","159992","06978","BK0239"],"gpt_icon":0},{"id":"2484153925","title":"盟科药业-U上涨5% 创新药发展受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2484153925","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484153925?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:02","pubTimestamp":1732078965,"startTime":"0","endTime":"0","summary":"11月20日，盟科药业-U股价大幅上涨，截至13点02分，盟科药业-U上涨5.13%，报5.33元/股，成交3210万元，换手率1.69%，振幅5.92%。资金动向截止发稿，盟科药业-U获得主力净流入5万元，其中超大单流出209万元，大单流入215万元。主营业务及业绩盟科药业-U公司主营业务为一家以治疗感染性疾病为核心，拥有全球自主知识产权和国际竞争力的创新药企业，致力于发现、开发和商业化针对未满足临床需求的创新药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120130353abd103d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120130353abd103d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","159992","BK0239"],"gpt_icon":0},{"id":"2484330821","title":"创新药板块震荡走强 贝达药业涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484330821","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484330821?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:17","pubTimestamp":1732069020,"startTime":"0","endTime":"0","summary":"专题：国内外宏观事件依次落地 A股配置机遇与挑战并存\n 11月20日消息，贝达药业、益方生物涨超10%，智翔金泰、诺思格、泰格医药、诺诚健华、海思科等涨逾7%。\n 消息面上，信银（香港）资本研究部的统计显示，创新药IND、NDA数量在经过2022年低位后重回增长，今年Q3药物临床获批1033个，同比增长25%，1类创新药获批上市共8个，同比翻了一倍。信银（香港）资本研究部认为，国产创新药正加速进入“新质发展阶段”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王其霖","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2024-11-20/doc-incwspws5452451.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2024-11-20/doc-incwspws5452451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1161","BK1574","BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2484621860","title":"中国医药：医疗设备招标有望复苏，创新药出海成果丰硕","url":"https://stock-news.laohu8.com/highlight/detail?id=2484621860","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484621860?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:07","pubTimestamp":1731931668,"startTime":"0","endTime":"0","summary":"MSCI中国医疗指数年初至今累计下跌17.9%，跑输MSCI中国指数32.4%。CXO板块有望受益于海外研发需求复苏，《生物安全法案》的影响或将有限。随着国内经济刺激政策实施，医疗设备更新的落地进度有望加快。创新药出海成果丰硕，交易类型多样。MNC药企延续在中国“扫货”的势头，加速引进中国创新药资产以丰富自身管线。预计新版医保药品目录将于11月底对外发布，明年1月1日起正式实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118200754a242edf1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118200754a242edf1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0010","BK0188","159992","BK0175","BK0028","159873","BK0082","600056","BK0250","BK0185"],"gpt_icon":0},{"id":"2484645719","title":"海思科最新公告：获得创新药HSK44459片IND申请《受理通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2484645719","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484645719?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:09","pubTimestamp":1731920987,"startTime":"0","endTime":"0","summary":"海思科公告，公司近日收到国家药品监督管理局下发的《受理通知书》，HSK44459片剂型药物拟用于白塞病治疗的境内生产药品注册临床试验申请获得受理。HSK44459片是公司自主研发的全新药物，属于化学药品1类。临床前研究显示，该药物靶点明确、疗效确切、安全性好，有望成为白塞病的有效治疗药物并解决目前临床用药匮乏的难题。公司此前已获得该药物“间质性肺疾病”适应症的《临床试验通知书》，目前正在进行Ⅰ期临床研究。本次为白塞病适应症的临床试验申请。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800022027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1574","BK0033","06978","BK1161","159992","BK0077","002653","BK0239","BK0028"],"gpt_icon":0},{"id":"2484645398","title":"海思科(002653.SZ)创新药HSK44459片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484645398","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484645398?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:09","pubTimestamp":1731920982,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的创新药HSK44459片境内生产药品注册临床试验申请《受理通知书》，该药品适应症：拟用于白塞病的治疗。贝赫切特病又称白塞病(Behcet’sdisease)，是一种以血管炎为基础病理改变的慢性、复发性自身免疫/炎症性疾病。主要表现为反复发作的口腔溃疡、生殖器溃疡、葡萄膜炎和皮肤损害，亦可累及周围血管、心脏、神经系统、胃肠道、关节、肺、肾等器官。HSK44459片是公司自主研发的一个全新的具有独立知识产权的治疗白塞病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0028","BK0188","03347","06978","BK1161","BK1583","BK0033","BK0239","002653","159992","BK1576","BK1574","BK1141"],"gpt_icon":0},{"id":"2484342645","title":"健康元：公司新型小分子糖皮质激素创新药目前正在准备IND阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2484342645","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484342645?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:00","pubTimestamp":1731920430,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问董秘，贵公司官网上推出新一代糖皮质激素创新药的介绍，请问在国家对新的创新药审批流程简化的背景下，贵公司这款新药预计需要多久才能上市，谢谢！健康元（600380.SH）11月18日在投资者互动平台表示，公司新型小分子糖皮质激素创新药目前正在准备IND阶段，由于创新药的研发周期长，距离上市时间还较远。近年来，公司已聚焦呼吸领域建立了较为丰富的创新药管线，目前已有5款呼吸创新药推进到II期以后，公司将发挥自身技术和资源优势，加快创新药研发进度，争取早日商业化(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118170146a24283c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118170146a24283c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0114","BK0028","600380","BK0046","159992","BK0077","BK0239","BK0188"],"gpt_icon":0},{"id":"2484619374","title":"国盛证券：国内创新药产业趋势由license-in逐步转为license-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2484619374","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484619374?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:00","pubTimestamp":1731913225,"startTime":"0","endTime":"0","summary":"License-in方面，国内药企引入项目数量和交易金额在2021年达到顶峰后逐年回落；至2024Q3项目引入活跃度进一步降低，聚焦临床中后期或已获批上市品种； License-out方面，国内药企达成对外授权合作的项目数量和交易金额稳步增长。国产新药license-out交易量价齐升，创新属性明显、技术多元2019-2024Q3期间国产新药license-out交易有量有质，本土创新逐步收获全球产业认可。从License-out适应症来看，肿瘤仍是目前的出海主力，2023年肿瘤License-out项目占比为54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU0196878994.USD","161027","BK1589","06990","06978","159992","BK1161","06855","BK1583","BK1191","03692"],"gpt_icon":0},{"id":"2484693949","title":"创新药龙头百济神州：造血能力不足三季报续亏，“烧钱模式”不休","url":"https://stock-news.laohu8.com/highlight/detail?id=2484693949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484693949?lang=zh_cn&edition=full","pubTime":"2024-11-18 11:13","pubTimestamp":1731899604,"startTime":"0","endTime":"0","summary":"11月13日-15日，创新药龙头百济神州股价持续阴跌，这背后或源于三季报成绩单不能让投资者满意。而2017年至今，百济神州长期处于“失血”状态，累计亏近580亿元。财报显示，今年前三季度百济神州实现营业收入191.36亿元，同比增长48.6%。对于最晚获批的百汇泽，百济神州在三季报中没有提及。百济神州前三季度的研发费用支出为101.66亿元，较上年同期有所增长。经计算，百济神州7年零9个月期间累计亏损近580亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024111800008242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1500","BK0239","LU0307460666.USD","LU2328871848.SGD","BK1161","BK1583","LU1969619763.USD","BK1588","06160","159992","688235","LU0588546209.SGD","BK1574"],"gpt_icon":0},{"id":"2484663903","title":"科伦药业(002422.SZ)：创新药物SKB535新药临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484663903","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484663903?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:18","pubTimestamp":1731889087,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业 发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司已于2024年11月15日收到国家药品监督管理局药品审评中心批准其开发的创新药物SKB535新药临床试验申请的临床试验通知书。根据NMPA官网公布，SKB535为NMPA批准的首个优化创新药临床试验审评审批试点项目，审评审批用时21日。待达到特定开发及销售里程碑后，科伦博泰将有权收取进一步里程碑付款及SKB535商业化后按净销售额计算的分级特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","06978","002422","BK1574","03347","LU2148510915.USD","BK1141","BK0239","LU1064130708.USD","LU1064131003.USD","BK1576","BK0060","BK1161","159992"],"gpt_icon":0},{"id":"2484891396","title":"众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2484891396","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484891396?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:41","pubTimestamp":1731840110,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","002317","BK0077","BK0188","BK1574","03347","159837","BK1141","BK0239","BK1576","06978","BK1161","159992"],"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":-0.0166},{"period":"1month","weight":-0.0339},{"period":"3month","weight":0.1827},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.1881},{"period":"ytd","weight":-0.137}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"serverTime":1732335504216,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}